Myriad International GmbH develops modern diagnostic agents that not only facilitate determining the proper course of treatment, but also take high scientific standards and the practical demands on practicality in daily work at the clinic into account.
Myriad International manufactures the EndoPredict test, a kit-based gene expression test to accurately determine the likelihood of distant cancer recurrence 10 years after diagnosis of primary breast cancer under solely anti-hormonal treatment, i.e. without chemotherapy.
This test was developed by Sividon Diagnostics GmbH, a leading breast cancer prognostic company which was a management buyout of Siemens Healthcare Diagnostics in 2010. Sividon Diagnostics was acquired by Myriad Genetics on May 31, 2016 and was renamed to Myriad International GmbH in February 2018.
About Myriad Genetics:
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five strategic imperatives: build upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please visit the Company’s website: www.myriad.com.